In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marnac Inc.

www.marnac.com

Latest From Marnac Inc.

Roche's pirfenidone bet validates Shanghai Genomics' venture

China was probably not a major consideration in Roche's $8bn-plus bet on US biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.

Orthopedics Respiratory

Shionogi takes InterMune to US court, claiming unpaid EU royalties for Esbriet

Shionogi has lodged a legal action in the US against InterMune, claiming that the US firm has failed to pay due royalties on sales of the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) in the EU.

Orthopedics Respiratory

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011

Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.

BioPharmaceutical Deals

Roche buys full rights to danoprevir from InterMune

Roche has bought full global development and commercialisation rights to danoprevir (RG7227/ITMN-191) from InterMune for $175 million, leaving InterMune with the troublesome pirfenidone as its principal in-house asset.

Orthopedics Respiratory
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Marnac Inc.
  • Senior Management
  • Shri N Giri, VP, Pharma. R&D
    Solomon B Margolin, PhD, Pres.
  • Contact Info
  • Marnac Inc.
    Phone: (214) 692-8544
    9400 N. Central Expressway
    Ste. 305
    Dallas, TX 75231
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register